ANX005 in Guillain-Barré syndrome (GBS): First-in-kind monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain has the potential to be the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback